Vectura Share Discussion Threads

[pooroldboy55] 27/1/2017 10:02

if only looks like some one knows something we dont!!!!!!

[soundbuy] 27/1/2017 09:44

Meaty vols early doors, somebody dumping, good job there's a level playing field out there...

[alexchry] 27/1/2017 09:01

pob55-downtrend has started earlier than usual today, rather worrying!

[cumnor] 26/1/2017 14:58

I hold these from around 136-7. Did well out of SKP and bought in here recently largely out of that but also VEC good stable of products as well. Solid company medium term but there is a big seller determined to get out and this could go on for a while. Anyone with an ounce of sense wont buy in AM as selling into to rises inevitable. I will add but happy if sellers forced out in the £1-£1.10 range so let them sweat it. (short term share price movements in these companies does not bother me and imo should be taken advaanttage of) imo

[pooroldboy55] 26/1/2017 14:43

But there has to be more to this up am down pm day after day something going on .But what? why would anyone buy am knowing cheaper later in the day

[aceuk] 26/1/2017 14:29

We do know that health and medicine are inordinately expensive and we do know that Trump (just like the British government) is focussed on the cost of new drugs and treatments. Trump will likely have more success than the British government as he appears (at this stage) a law unto himself.

Not sure why Vectura should get tarred with the same brush as Pfizer, Horizon, Glaxo, etc. but all boats fall and rise with the tide.

[pooroldboy55] 26/1/2017 14:18

Ace .You could be right but we just dont know!!!!

[a1ord53] 26/1/2017 14:09

I am asking all : Where is architect of Vectura and merger with Sky Pharma so called Biotech Guru Mr Woodford ?
He was always buying in time of share price depreciation , but not in after merger time yet .Or he lost his magic touch ? His another creation BTG also loosing ground and all high target prices moving down. Analysts were all wrong.
The same analysts of Vectura. Same people same high estimates and same results - share price down down.
Vectura was almost 2 £!
Whats happened ? Any views or ideas ?

[pooroldboy55] 26/1/2017 11:44

Getting near midday and down trend on as normal

[pooroldboy55] 26/1/2017 08:57

Hi diesel
That's how I see it perhaps ex skp selling, if like me in at an average under 80p

[diesel] 26/1/2017 08:21

Maybe another up in the morning down in the afternoon, but there is clearly a selling strategy that sells into the strength of good news.

[dontay] 25/1/2017 18:09

There has been no profits reported for the last five years. (That MAY change this year as a result of the merger) There is no reason to suspect the Asian trial will report come any different to the European results. There is the GSK litigation issues which are expected to have a material impact on 2017 figures unless resolved. It's very likely that several major shareholders who held stock on both companies prior the merger are still adjusting their weightings which has resulted in a considerable overhang which will take a while to work through.It's no surprise that the share price is depressed at the moment.

[carpadium] 25/1/2017 17:07

Well VEC seem about as popular as a dose of the clap right now despite solid, if not spectacular, progress reported so far this year. Expectations met is about the best that can be said, without any nice surprises.

Two weeks ago to the day VEC showed an intra-day high of 147.17, since then and Trump's take on global pharma, we've now lost 10.2%. FWIW looking at others, in the same two weeks AZN have lost 10%, SHP 10.1%, GSK 5.2% whilst Hikma, heavily hit on the day has recovered to only 4.2% down.

But, remain hopeful that key corporate news, as a result of CEO's stated course, will re-ignite VEC and occur prior to Advair decision.

[a1ord53] 25/1/2017 16:21

So where are analysts who predicted atleast 2 £ share price .
Paid by company recommendations imo.
We are in Vectura and paid by Vectura analysts scam.
Major shareholders responsible for this failure as well.
Woodford disappeared and not buying any more .
Like I wrote earlier shareholders lost trust and trying to safe what possible to safe !!!
I hope that after sell off , company will clear all unanswered issues like litigations , COPD trials in China and ...,,

[alexchry] 25/1/2017 12:31

From Novartis results-New data from two head-to-head studies showed Utibron Neohaler provided clinically meaningful and comparable bronchodilation to Anoro® Ellipta® in US patients with COPD, though the primary endpoint of non-inferiority was not met. Novartis out-licensed US commercialization rights for Utibron Neohaler, as well as Seebri Neohaler and Arcapta Neohaler, to Sunovion. This doesn't sound entirely positive, it reads as if Anoro Ellipta is better but not sure if that's the correct interpretation which may be why Novartis passed the marketing on to Sunovion.

[alexchry] 25/1/2017 09:16

pob55-some good news would help. Today's rns was only confirmation of what VEC had already predicted. Still no news of Asia COPD trial, no news of litigation, Ultibro marketing in US slipping from original forecasts, Europe COPD trial a failure, J W-L eager to spend money on a takeover. There has been precious little good news since the takeover except for continued good sales of existing marketed products so I'm not surprised the share price is weak. I wish I'd sold at the time of the takeover but I thought the logic was sound and the company would go from strength to strength. The Advair decision in May is very important, a knock back then could see new lows in the share price but I'm going to continue to hold and keep my fingers crossed.

[fhmktg] 25/1/2017 09:10

Good phrase!

[bonnard] 25/1/2017 09:03

Patients and Patience

[pooroldboy55] 25/1/2017 08:58

and the price goes down what will it take to move this forward?

[richtea1701] 25/1/2017 07:50

Clearly bust

[gbcol] 25/1/2017 07:27

Another positive RNS this morning

[pooroldboy55] 24/1/2017 16:29

Well thats that then!!!!!!! Simple